Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our high-tech, dedicated method is applied to construct targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q9BYV2

UPID:
TRI54_HUMAN

ALTERNATIVE NAMES:
Muscle-specific RING finger protein; Muscle-specific RING finger protein 3; RING finger protein 30

ALTERNATIVE UPACC:
Q9BYV2; A5D8T7; Q53SY4; Q9BYV3

BACKGROUND:
The protein Tripartite motif-containing protein 54, with alternative names such as Muscle-specific RING finger protein 3 and RING finger protein 30, is essential for myotubes formation. It achieves this by possibly binding to and stabilizing microtubules, indicating its significant role in muscle development.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Tripartite motif-containing protein 54 offers a promising avenue for therapeutic intervention. Given its critical role in muscle development, targeting this protein could lead to innovative treatments for muscle-related conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.